BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update
November 05 2019 - 6:15AM
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading
developer of adult stem cell therapies for neurodegenerative
diseases, today announced that the Company will hold a conference
call to update shareholders on financial results for the third
quarter ended September 30, 2019, and provide a corporate update,
at 8:00 a.m., Eastern Standard Time, on Thursday, November 14,
2019.
BrainStorm’s President & CEO, Chaim
Lebovits, will present a corporate update, after which, participant
questions will be answered. Joining Mr. Lebovits to answer
investment community questions will be Ralph Kern, MD, MHSc, Chief
Operating Officer and Chief Medical Officer, and Preetam Shah, PhD,
Chief Financial Officer.
Participants are encouraged to submit their
questions prior to the call by sending them to:
q@brainstorm-cell.com; Questions
should be submitted by 5:00 p.m., Eastern Standard
Time, Tuesday, November 12.
The investment community may participate in the
conference call by dialing the following numbers:
Toll
Free: |
Toll
Free: 1-877-423-9813 |
Toll/International: |
1-201-689-8573 |
Audio Webcast: |
Link to Webcast |
Those interested in listening to the conference
call live via the internet may do so by visiting the “Investors
& Media” page of BrainStorm’s website at
www.ir.brainstorm-cell.com and clicking on the conference call
link.
A webcast replay of the conference call will be
available for 30 days on the “Investors & Media” page of
BrainStorm’s website:
Toll
Free: |
1-844-512-2921 |
Toll/International: |
1-412-317-6671 |
Replay Pin Number: |
13696529 |
Replay Start: |
Thursday, November 14, 2019, 11:00 AM ET |
Replay Expiry: |
Thursday, November 28, 2019, 11:59 PM ET |
About NurOwn®NurOwn® (autologous MSC-NTF) cells
represent a promising investigational therapeutic approach to
targeting disease pathways important in neurodegenerative
disorders. MSC-NTF cells are produced from autologous, bone
marrow-derived mesenchymal stem cells (MSCs) that have been
expanded and differentiated ex vivo. MSCs are converted into
MSC-NTF cells by growing them under patented conditions that induce
the cells to secrete high levels of neurotrophic factors.
Autologous MSC-NTF cells can effectively deliver multiple NTFs and
immunomodulatory cytokines directly to the site of damage to elicit
a desired biological effect and ultimately slow or stabilize
disease progression. BrainStorm has fully enrolled a Phase 3
pivotal trial of autologous MSC-NTF cells for the treatment of
amyotrophic lateral sclerosis (ALS). BrainStorm also recently
received U.S. FDA acceptance to initiate a Phase 2 open-label
multicenter trial in progressive MS and enrollment began in March
2019.
About BrainStorm Cell Therapeutics
Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of
innovative autologous adult stem cell therapeutics for debilitating
neurodegenerative diseases. The Company holds the rights to
clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six U.S. sites
supported by a grant from the California Institute for Regenerative
Medicine (CIRM CLIN2-0989). The pivotal study is intended to
support a filing for U.S. FDA approval of autologous MSC-NTF cells
in ALS. BrainStorm also recently received U.S. FDA clearance to
initiate a Phase 2 open-label multicenter trial in progressive
Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells
in patients with progressive MS (NCT03799718) started enrollment in
March 2019. For more information, visit the company's website at
www.brainstorm-cell.com
Safe-Harbor
Statement
Statements in this announcement other than
historical data and information, including statements regarding
future clinical trial enrollment and data, constitute
"forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics
Inc.'s actual results to differ materially from those stated
or implied by such forward-looking statements. Terms and phrases
such as "may", "should", "would", "could", "will", "expect",
"likely", "believe", "plan", "estimate", "predict", "potential",
and similar terms and phrases are intended to identify these
forward-looking statements. The potential risks and uncertainties
include, without limitation, BrainStorm’s need to raise additional
capital, BrainStorm’s ability to continue as a going concern,
regulatory approval of BrainStorm’s NurOwn® treatment candidate,
the success of BrainStorm’s product development programs and
research, regulatory and personnel issues, development of a global
market for our services, the ability to secure and maintain
research institutions to conduct our clinical trials, the ability
to generate significant revenue, the ability of BrainStorm’s
NurOwn® treatment candidate to achieve broad acceptance as a
treatment option for ALS or other neurodegenerative diseases,
BrainStorm’s ability to manufacture and commercialize the NurOwn®
treatment candidate, obtaining patents that provide meaningful
protection, competition and market developments, BrainStorm’s
ability to protect our intellectual property from infringement by
third parties, heath reform legislation, demand for our services,
currency exchange rates and product liability claims and
litigation,; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACTS
Corporate: Uri Yablonka Chief
Business Officer BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188 uri@brainstorm-cell.com
Media: Sean Leous Westwicke/ICR PR Phone:
+1.646.677.1839 sean.leous@icrinc.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024